The global Janus Kinase (JAK) Inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). JAK inhibitors are an oral class of therapeutics that are gaining traction owing to an increase in the number of Immune-Mediated Inflammatory Diseases (IMIDs) treatments across the globe. JAK consists of four intracellular non-receptor tyrosine kinases that enable cytokine-mediated signalling through the JAK-STAT pathway. It contains two nearly identical phosphate-transferring domains, in which one domain shows kinase activity and the other regulates the activity of the first via negative inhibition. The four receptors in the JAK family are JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). The mutation in any of these can lead to various medical conditions.
A full report of Janus Kinase (JAK) Inhibitors Therapy Market is available at: https://www.omrglobal.com/industry-reports/janus-kinase-jak-inhibitors-therapy-market
Clinical results of JAK inhibitors promise patients effective and more convenient treatment options in multiple indications when compared to the traditional treatments approach. The first of them to enter the market, with approval for Rheumatoid Arthritis (RA), were tofacitinib (now also approved for Psoriatic Arthritis and Ulcerative Colitis) and baricitinib, followed by upadacitinib (RA). Moreover, with the increasing prevalence of arthritis across the globe, the global market for JAK inhibitors is also expected to witness a rapid pace. According to the Arthritis Foundation, arthritis affects more than 1 in 4 adults. Moreover, by 2040, the number of adults in the US with doctor-diagnosed arthritis is projected to increase 49% to 78.4 million (25.9% of all adults). The number of adults reporting activity limitations due to their arthritis will increase 52% to 34.6 million (11.4% of all adults).
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/janus-kinase-jak-inhibitors-therapy-market
Some key players operating in the market include Eli Lilly, Astellas, Pfizer, Baxter, Novartis, Abbvie, Sierra Oncology, CTI BioPharma, and Incyte and others. These players are eyeing to strengthen their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
- Competitive Landscape: Eli Lilly, Astellas, Pfizer, Baxter, Novartis, Abbvie, Sierra Oncology, CTI BioPharma, and Incyte and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Janus Kinase (JAK) Inhibitors Therapy Market by Segment
By Application
• Autoimmune Disorders
• Oncology
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
